WO1996028244A1 - Composition for stabilizing a suspension and pharmaceutical uses of said composition and of said suspension - Google Patents
Composition for stabilizing a suspension and pharmaceutical uses of said composition and of said suspension Download PDFInfo
- Publication number
- WO1996028244A1 WO1996028244A1 PCT/BE1996/000028 BE9600028W WO9628244A1 WO 1996028244 A1 WO1996028244 A1 WO 1996028244A1 BE 9600028 W BE9600028 W BE 9600028W WO 9628244 A1 WO9628244 A1 WO 9628244A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- particles
- composition
- suspension
- solid particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
- C09K23/017—Mixtures of compounds
- C09K23/018—Mixtures of two or more different organic oxygen-containing compounds
Definitions
- composition for stabilizing a suspension and pharmaceutical uses of said composition and of said suspension
- the present invention relates to a composition for stabilizing a suspension or an emulsion of liquid or solid particles, preferably pharmaceutical suspension, food suspension, phyto-pharmaceutical suspension, ....
- the invention relates also to the preparation of a hydrophilic matrix with a controlled release.
- the stabilization of a suspension of solid particles is of major importance * for avoiding solid particles to form a deposit which can no more or with difficulty be suspended, and * for avoiding a too rapid coalescence and creaming of oil droplets to form large oil drops.
- Xanthan gum is known as a thickening agent for aqueous liquid medium and is an agent used for the preparation of hydrophilic matrix.
- N-octenylsuccinate starch is known as agent for increasing the solubility (International Journal of Pharmaceutics - 1993 - Elsevier Science Publishers B.V.- pages 23-27 - Remon et al) and as thickener agent for aqueous medium.
- a first subject matter of the invention is a composition containing Xanthan gum and a N- octenylsuccinate starch.
- a composition for example in the form of dry powders, can be added to a suspension containing solid particles, for example an aqueous suspension possibly containg a solvent, an organic solvent, so as to stabilize the particles in said suspension.
- the composition of the invention is thus a composition for stabilizing a suspension of solid particles or an emulsion of liquid droplets, preferably pharmaceutical suspension, food suspension, phyto- pharmaceutical suspension, ....
- the weigth ratio Xanthan gum / N- octenylsuccinate starch in the composition is between 1/20 and 20/1, preferably between 1/15 and 15/1.
- the weigth ratio Xanthan gum / N-octenylsuccinate starch is higher than 1/5, advantageously higher than 1/4, but preferably lower than 1/1.
- the suspension of drug solid particles is stable and has a slow release of drug.
- a matrix made from such a composition has also a slow release rate.
- the weigth ratio Xanthan gum / N-octenylsuccinate starch is lower than 1/5, preferably lower than 1/8, for example 1/10.
- Matrix made from such a composition which will be decomposed after administration (i.e. making a kind of suspension in the stomach) , has a high release rate.
- composition of the invention has preferably the form of a mixture of dry particles.
- said composition may have other forms, such as the form of a liquid (for example, an aqueous medium containing Xanthan gum and N-octenylsuccinate starch) , a pasta, ...
- the composition as described above is mixed with solid drug, said composition being mixed with a pharmaceutical drug containing solid particles before oral administration of the drug containing particles and/or during the oral administration of the drug containing particles and/or after the administration of the drug containing particles, so as to control the release of the drug administered.
- the invention relates also to a suspension of solid particles, said suspension containing a composition as described above for increasing the stability of the suspension.
- the weight ratio solid particles to be suspended / composition according to the invention is between 15/1 and 1/15, preferably between 10/1 and 1/3, most preferably between 1/1 and 1/2.5.
- a further subject matter of the invention is a pharmaceutical drug form (pills, pellets, compressed tablets, ... ) containing :
- the solid drug particles or solid particles containing a mixture of said drug and a solvent for said drug are dispersed into a matrix, the composition of which is a composition of the invention.
- the weight ratio solid particles / composition Xanthan gum + N-octenylsuccinate starch is between 15/1 and 1/15, preferably between 10/1 and 1/3, most preferably between 1/1 and 1/2.5.
- the solid particles are microcrystalline particles containing the drug suspended in a solvent .
- the weight ratio Xanthan gum / N- octenylsuccinate starch of the pharmaceutical form is lower than 1/5, preferably lower than 1/8, for example 1/10 or lower than 1/10, whereby a higher release rate of the drug can be achieved at least 1 hour after administration, said higher release rate being substantially constant from a total release of 20% of the drug up to a total release of the drug of 90%.
- the weight ratio Xanthan gum / N-octenylsuccinate starch of the pharmaceutical form is higher than 1/5, advantageously higher than 1/4, but preferably lower than 1/1, whereby a slow release rate of the drug can be achieved at least 1 hour after administration, said slow release rate being substantially constant at least from a total release of 20% of the drug up to a total release of the drug of 90%.
- the pharmaceutical drug form is preferably a compressed mixture of drug containing particles, particles of Xanthan gum and particles of N- octenylsuccinate starch.
- the weight ratio drug containing particles / composition as described above is between 10/1 and 1/2.
- the weight ratio drug containing particles / Xanthan gum is greater than 3/1, while the weight ratio drug containing particles / N- octenylsuccinate starch is lower than 3/1, most preferably between 1.5/1 and 1/4.
- the invention relates further to drug containing solid particles covered with a layer having a composition as disclosed above.
- the solid particles (advantageously microcrystalline particles) contain the drug and a solvent of said drug.
- a still further subject matter of the invention is the use of a composition as disclosed above for increasing the efficiency of a pharmaceutical drug.
- Fig 1 shows the release of drug containing pharmaceutical form
- - Fig 2 to 5 show the stability of suspensions
- Ibuprofen in the form of dry particles has been mixed with dry particles of Xanthan gum (Gum) and dry particules of N-octenylsuccinate starch (Sta.) . The so obtained mixture has then be mixed with magnesium stearate (Mag. ) .
- the particles mixture has then been compressed (pressure of about 130 MPa) into tablets having a diameter of 9 mm.
- the release of tablet 1 was lower than the release of tablets 2 and 3.
- a 80% release was obtained for tablet 1 after 24 hours, while said 80 % release was obtained after 8 hours for tablet 2, and after 10 hours for tablet 3.
- the release rate was substantially constant for the tablets 2, said release rate being about 13%/hour.
- said high initial rate occurs about 1 hour after the beginning of the release, and being about 19% release instead of an expected value of about 13%.
- such an initial high release occurs also about 1 hour after the beginning of the release, and being of about 26% release, instead of an expected value of about IG ⁇ . It means that when no N-octenylsuccinate starch is used, the initial release after 1 hour is more than 2.5 times higher than the expected release rate, while when using N-octenylsuccinate starch, the initial release rate is less than about 50% higher than the expected release.
- the release rate of tablet 4 was still lower than the release rate of tablet 2.
- Suspensions of particles of paracetamol in 100 ml water have been prepared.
- the composition of the prepared suspensions is given below : Suspension SI S2 S3 S4
- the suspensions have been analyzed just after preparation ( ) ; 2 months after preparation ( ) ; 1 year after preparation without stirring or shaking and at a temperature of 20°C ( ) , and 1 year after preparation with stirring and/or shaking and with a temperature varying between 10 and 50°C ( ) .
- N-octenylsuccinate starch By using N-octenylsuccinate starch, it was possible to reduce the increase of the number of particles with a diameter larger than 75 ⁇ m and 105 ⁇ m to less than 10- 15 % (- increase between the number of particles 1 year after preparation and just after preparation) , i.e. a relative increase of less than (62-50/50) about 25% for the number of particles with a diameter larger than 70 ⁇ m.
- Fig 3 and 4 show also that the number of particles with a diameter larger than 105 ⁇ m remains substantially constant and that said number (1 year after preparation) is substantially the same for the suspension without shaking and with shaking.
- the particles of the suspension had a better stability, stability which was not dependent from the temperature and of the shaking or not.
- the simultaneous use of Xanthan gum and a N-octenylsuccinate starch acts as means for reducing the formation of larger particles and reduces the recrystallisation of larger particles.
- Xanthan gum and a N-octenylsuccinate starch has the advantage that 1 year after preparation, said suspension will have the same or substantially the same property or efficiency. Indeed, as t.-.a formation of larger particles is reduced or avoided (said particles forming a deposit on the bottom which can no more be suspended) , the drug content of the suspension remains substantially constant or the same just after preparation and one year after preparation. Furthermore, as the mean diameter of the particles just after preparation and the mean diameter of the particles one year after preparation will be substantially equal (there is no or substantially no formation of large particles) the efficiency of the particles suspended which depends of the size of the particles will remain substantially constant during at least one year.
- the simultaneous use of Xanthan gum and a N- octenylsuccinate starch seems also to increase the efficiency of a drug, pharmaceutical active agent in a patient. This better efficiency seems to be due to a better repartition or dispersion of the pharmaceutical solid drug in the stomach of the patient, in the mouth of the patient, in the gastro intestinal track, ....
- the composition containing Xanthan gum and a N- octenylsuccinate starch can be mixed with pharmaceutical drug containing solid particles before oral administration of the drug containing particles and/or during the oral administration of the drug containing particles and/or after the administration of the drug containing particles, so as to control the release of the drug.
- the suspensions 2 to 4 have been dried, whereby drug particles covered with a layer comprising Xanthan gum and a N-octenylsuccinate starch have been prepared.
- Said dried solid particles were suitable for the preparation of suspensions, for example aqueous suspension, said suspension being for example prepared just before oral administration.
- a further suspension has been prepared.
- the suspension was obtained by mixing ( under stirring and at a temperature of 45°C) nifedipine (5g) , Polyethylene- glycol derivative (PEG-7, Henkel, Cetiol HE, a solvent for nifedipine) (60g) ; water (300g) and microcrystalline cellulose (50g) .
- nifedipine Polyethylene- glycol derivative
- PEG-7 Polyethylene- glycol derivative
- Cetiol HE a solvent for nifedipine
- microcrystalline cellulose 50g
- the suspension was a suspension of solid particles (microcrystalline particles) containing drug (nifedipine) and a solvent for said drug (PEG-7) , i.e. drug dissolved in the solvent .
- Said suspension has been dried at a temperature of about 50°C, so as to obtain solid particles containing drug (nifedipine) and a solvent for said drug (PEG-7) , i.e. drug dissolved in the solvent, said particles being covered with an outer layer comprising Xanthan gum and a N-octenylsuccinate starch.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96905621A EP0814899A1 (en) | 1995-03-14 | 1996-03-14 | Composition for stabilizing a suspension and pharmaceutical uses of said composition and of said suspension |
AU49339/96A AU4933996A (en) | 1995-03-14 | 1996-03-14 | Composition for stabilizing a suspension and pharmaceutical uses of said composition and of said suspension |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE9500222 | 1995-03-14 | ||
BE9500222A BE1009380A3 (en) | 1995-03-14 | 1995-03-14 | Stabilizing COMPOSITION FOR SUSPENSION. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996028244A1 true WO1996028244A1 (en) | 1996-09-19 |
Family
ID=3888845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BE1996/000028 WO1996028244A1 (en) | 1995-03-14 | 1996-03-14 | Composition for stabilizing a suspension and pharmaceutical uses of said composition and of said suspension |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0814899A1 (en) |
AU (1) | AU4933996A (en) |
BE (1) | BE1009380A3 (en) |
WO (1) | WO1996028244A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998015191A1 (en) * | 1996-10-09 | 1998-04-16 | Givaudan-Roure (International) S.A. | Process for preparing beads as food or tobacco additive |
WO1998015192A1 (en) * | 1996-10-09 | 1998-04-16 | Givaudan-Roure (International) S.A. | Process for preparing beads as food additive |
WO2005099674A1 (en) | 2004-04-14 | 2005-10-27 | Vectura Limited | Pharmaceutical compositions comprising an amphiphilic starch |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3091567A (en) * | 1961-02-17 | 1963-05-28 | Nat Starch Chem Corp | Encapsulating agents with controlled water repellency |
FR2214470A1 (en) * | 1973-01-18 | 1974-08-19 | Hoffmann La Roche | |
FR2383696A1 (en) * | 1977-03-18 | 1978-10-13 | Hercules Powder Co Ltd | PROCESS FOR FORMING A STABLE SUSPENSION OF SOLID PARTICLES |
EP0006294A1 (en) * | 1978-05-30 | 1980-01-09 | Imperial Chemical Industries Plc | Comminution process and products thus obtained |
WO1987005212A1 (en) * | 1986-03-07 | 1987-09-11 | Eurand Italia S.P.A. | Formulation for preparing sustained release drugs for oral administration |
EP0332027A1 (en) * | 1988-03-11 | 1989-09-13 | National Starch and Chemical Corporation | Modified starch emulsifier characterized by shelf stability |
EP0358528A2 (en) * | 1988-09-09 | 1990-03-14 | Unilever Plc | Cosmetic composition |
EP0360562A2 (en) * | 1988-09-19 | 1990-03-28 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
US4994264A (en) * | 1989-12-15 | 1991-02-19 | Revlon, Inc. | Press molded cosmetic composition with pay off |
WO1992000731A1 (en) * | 1990-07-11 | 1992-01-23 | Eurand International Spa | Pharmaceutical composition for rapid suspension in water |
EP0477061A1 (en) * | 1990-09-07 | 1992-03-25 | Pierre Fabre Medicament | Tablet of Isosorbide-5-Mononitrate with sustained release and its process of preparation |
JPH06225720A (en) * | 1993-02-01 | 1994-08-16 | Kanegafuchi Chem Ind Co Ltd | Foamable oil-in-water type emulsified composition |
US5338560A (en) * | 1992-06-16 | 1994-08-16 | Van Den Bergh Foods Company, Division Of Conopco, Inc. | Edible plastic dispersion having a rapid gel-setting starch |
WO1995006458A1 (en) * | 1993-09-01 | 1995-03-09 | Unilever Plc | Petroleum jelly cream |
-
1995
- 1995-03-14 BE BE9500222A patent/BE1009380A3/en not_active IP Right Cessation
-
1996
- 1996-03-14 WO PCT/BE1996/000028 patent/WO1996028244A1/en not_active Application Discontinuation
- 1996-03-14 AU AU49339/96A patent/AU4933996A/en not_active Abandoned
- 1996-03-14 EP EP96905621A patent/EP0814899A1/en not_active Withdrawn
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3091567A (en) * | 1961-02-17 | 1963-05-28 | Nat Starch Chem Corp | Encapsulating agents with controlled water repellency |
FR2214470A1 (en) * | 1973-01-18 | 1974-08-19 | Hoffmann La Roche | |
FR2383696A1 (en) * | 1977-03-18 | 1978-10-13 | Hercules Powder Co Ltd | PROCESS FOR FORMING A STABLE SUSPENSION OF SOLID PARTICLES |
EP0006294A1 (en) * | 1978-05-30 | 1980-01-09 | Imperial Chemical Industries Plc | Comminution process and products thus obtained |
WO1987005212A1 (en) * | 1986-03-07 | 1987-09-11 | Eurand Italia S.P.A. | Formulation for preparing sustained release drugs for oral administration |
EP0332027A1 (en) * | 1988-03-11 | 1989-09-13 | National Starch and Chemical Corporation | Modified starch emulsifier characterized by shelf stability |
EP0358528A2 (en) * | 1988-09-09 | 1990-03-14 | Unilever Plc | Cosmetic composition |
EP0360562A2 (en) * | 1988-09-19 | 1990-03-28 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
US4994264A (en) * | 1989-12-15 | 1991-02-19 | Revlon, Inc. | Press molded cosmetic composition with pay off |
WO1992000731A1 (en) * | 1990-07-11 | 1992-01-23 | Eurand International Spa | Pharmaceutical composition for rapid suspension in water |
EP0477061A1 (en) * | 1990-09-07 | 1992-03-25 | Pierre Fabre Medicament | Tablet of Isosorbide-5-Mononitrate with sustained release and its process of preparation |
US5338560A (en) * | 1992-06-16 | 1994-08-16 | Van Den Bergh Foods Company, Division Of Conopco, Inc. | Edible plastic dispersion having a rapid gel-setting starch |
JPH06225720A (en) * | 1993-02-01 | 1994-08-16 | Kanegafuchi Chem Ind Co Ltd | Foamable oil-in-water type emulsified composition |
WO1995006458A1 (en) * | 1993-09-01 | 1995-03-09 | Unilever Plc | Petroleum jelly cream |
Non-Patent Citations (2)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 018, no. 597 (C - 1273) * |
REMON ET AL.: "LOW SUBSTITUTED N-OCTENYLSUCCINATE STARCH AS A DISSOLUTION RATE ENHANCER IN SOLID DOSAGE FORMS.", INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, AMSTERDAM-NL, pages 23 - 27, XP000563693 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998015191A1 (en) * | 1996-10-09 | 1998-04-16 | Givaudan-Roure (International) S.A. | Process for preparing beads as food or tobacco additive |
WO1998015192A1 (en) * | 1996-10-09 | 1998-04-16 | Givaudan-Roure (International) S.A. | Process for preparing beads as food additive |
US6325859B1 (en) | 1996-10-09 | 2001-12-04 | Givaudan Roure (International) Sa | Process for preparing beads as food or tobacco additive |
US6436461B1 (en) | 1996-10-09 | 2002-08-20 | Givauden Roure (International) Sa | Process for preparing gel beads as food additives |
EP1369043A1 (en) * | 1996-10-09 | 2003-12-10 | Givaudan SA | Process for preparing beads as food additive and use thereof |
US6929814B2 (en) * | 1996-10-09 | 2005-08-16 | Givaudan Sa | Process for preparing beads as food additive and product thereof |
WO2005099674A1 (en) | 2004-04-14 | 2005-10-27 | Vectura Limited | Pharmaceutical compositions comprising an amphiphilic starch |
JP2007532620A (en) * | 2004-04-14 | 2007-11-15 | ベクトゥラ・リミテッド | Pharmaceutical composition comprising amphiphilic starch |
Also Published As
Publication number | Publication date |
---|---|
EP0814899A1 (en) | 1998-01-07 |
BE1009380A3 (en) | 1997-03-04 |
AU4933996A (en) | 1996-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU639334B2 (en) | Taste masking and sustained release coatings for pharmaceuticals | |
US6261602B1 (en) | Pharmaceutical composition for rapid suspension in aqueous media | |
EP0430287B1 (en) | Sustained-release drug dosage units | |
US5354556A (en) | Controlled release powder and process for its preparation | |
EP0411952B1 (en) | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets | |
EP0377658B1 (en) | A free-flowing granular composition containing ibuprofen and a method for its preparation | |
US5238686A (en) | Sustained-release pharmaceutical preparation | |
KR0143424B1 (en) | Granules having core and their production | |
US5955107A (en) | Pharmaceutical suspension tablet compositions | |
US6099865A (en) | Croscarmellose taste masking | |
IE883583L (en) | Spray dried ibuprofen | |
PL142312B1 (en) | Process for preparing delayed-action preparation with bromohexyne | |
JPH0122245B2 (en) | ||
EP0267702A2 (en) | Spray dried acetaminophen | |
JP3285410B2 (en) | Oral pharmaceutical composition containing anthocyanosides | |
RU2207133C2 (en) | Tibolon-stabilizing compositions | |
EP0265226A2 (en) | Spray dried acetaminophen | |
EP0169236A1 (en) | Controlled release liquid dosage formulations for pharmaceuticals | |
EP0040472A2 (en) | Spray dried N-acetyl-p-aminophenol compositions and method for manufacture thereof | |
CA2252773C (en) | Taste masked pharmaceutical compositions | |
US4670251A (en) | Microcrystalline tableting excipient derived from whey | |
WO1996028244A1 (en) | Composition for stabilizing a suspension and pharmaceutical uses of said composition and of said suspension | |
JPS61212517A (en) | Long-acting tablet | |
WO1993012771A1 (en) | Prolamine coatings for taste-masking orally-administrable medicaments | |
Pongpaibul et al. | Preparation and in vitro dissolution characteristics of propranolol microcapsules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996905621 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 913335 Date of ref document: 19971112 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996905621 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996905621 Country of ref document: EP |